=Spark Therapeutics (ONCE) to be acquired by Roche (RHHBY) for $114.50 per share

Update 17 Dec 2019: Roche to complete $4.3 billion Spark deal as regulators give all clear: ZURICH/WASHINGTON (Reuters) - Swiss drugmaker Roche plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment.

  

• Spark Therapeutics (ONCE) announced that it has entered into a definitive merger agreement for Roche (RHHBY) to fully acquire Spark Therapeutics at a price of $114.50 per share in an all-cash transaction. This corresponds to a total equity value of approximately $4.8 billion on a fully diluted basis, inclusive of approximately $500 million of projected net cash expected at close. The per share price represents a premium of 122% to Spark's closing price on Feb. 22, 2019. The merger agreement has been unanimously approved by the boards of both Spark and Roche.
• Under the terms of the merger agreement, Roche will promptly commence a tender offer to acquire all outstanding shares of Spark's common stock, and Spark will file a recommendation statement containing the unanimous recommendation of the Spark board that Spark shareholders tender their shares to Roche.
• The closing of the transaction is expected to take place in the second quarter of 2019.